Head-to-head evidence
Envafolimab vs KL-A167
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-L1 · full Non-Small Cell Lung Cancer pipeline
Envafolimab
Developed by Suzhou Alphamab and partners
NCT05068427 · Phase 2 · completed
The study was an open-label, single-arm trial of 34 patients receiving chidamide plus envafolimab, with no randomized control group for comparison. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT05024214 (registry estimate)
KL-A167
Developed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07108816 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Envafolimab's landscape · KL-A167's landscape